HK Stock Market Move | POP MART (09992) rises more than 4%, LABUBU appears at the opening ceremony of the 2026 World Cup. The company's diversified business is accelerating.
Babymate (09992) rose over 4%, as of the end of the coverage, it increased by 3.98%, closing at HK$185.4, with a turnover of HK$2.798 billion.
POP MART (09992) rose more than 4%, as of the time of publication, it increased by 3.98% to 185.4 Hong Kong dollars, with a turnover of 2.798 billion Hong Kong dollars.
On the news front, on June 12, 2026, the opening ceremony of the 2026 FIFA World Cup in the United States, Canada, and Mexico officially started. The IP LABUBU under POP MART made an appearance as a special guest at the event, appearing on the world stage of sports. At the opening ceremony, two LABUBU characters dressed in jerseys made their first appearance at the World Cup, showcasing their cute and enthusiastic fan attitude, allowing Chinese original IP to make its mark on the international sports stage. The POP MART THE MONSTERS and FIFA World Cup joint series has been officially launched.
According to reports, POP MART's Chief Operating Officer recently disclosed for the first time the detailed data of the company's largest overseas market, stating that last year, non-Labubu products accounted for approximately 50% of total revenue in the U.S. market. In markets such as Japan, South Korea, and Southeast Asia, non-Labubu series products already dominate. Currently, POP MART is accelerating diversification, expanding Skullpanda, Hirono, and other characters, and collaborating with Sony Pictures to produce a Labubu movie, expected to be released in 2028.
Related Articles

QYUNS-B (02509) spent HKD 159,600 to buy back 10,000 shares on June 12th.

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.
QYUNS-B (02509) spent HKD 159,600 to buy back 10,000 shares on June 12th.

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

RECOMMEND





